In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

GreensKeeper Asset Management, an investment management company, released its first quarter 2025 investor letter. A copy of ...

With governments worldwide accelerating e-invoicing mandates and indirect tax regulations expanding, businesses face growing compliance challenges. The Vertex Chief Strategy Office plays a key role in ...

Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...

Leerink Partners analyst David Resinger warned his clients on Sunday that the tariff risks to the industry are ...

Vertex Pharma has chosen the three-drug combination it intends to submit for approval later this year for cystic fibrosis, in a bid to add another product to its stable. The US company has plumped ...

In this article, we are going to take a look at where Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) stands against other most expensive stocks insiders are dumping in March. After being in the ...

Vertex Pharmaceuticals (VRTX) announced several updates on the company’s type 1 diabetes portfolio. Vertex has completed enrollment and dosing in Parts A and B of the Phase 1/2 VX-264 study and ...

Conduit Pharmaceuticals reports advancements in lupus studies and trial designs. The Company partnered with Charles River Laboratories to conduct preclinical studies of glucokinase inhibitors for ...

Proficio Capital Partners cranked up its position in Vertex Pharmaceuticals by 46.6% during the fourth quarter, grabbing 978 shares worth $394,000. Other modest investors also dipped their toes in, ...